top of page

Eight Dragonfly-developed drugs are in clinical trials now, with our lead drug in Phase 2.  Four more Dragonfly-developed drugs are expected in the clinic by the end of 2024.

DRAGONFLY invents novel therapies that harness the body’s immune system for vastly improved Patient Outcomes.


We build drugs in autoimmune disease, oncology, fibrosis, neuro-inflammation, and beyond.

In collaboration with AbbVie, BMS, Gilead and Merck, our novel TriNKET® and CYTOKINE platforms have generated 11 Drug Candidates that have been handed off to partners.

Activating the Immune
System to Fight Disease


Milestone Payment Following Dosing of First Patient

Dragonfly's Clinical Collaboration with Gilead


 Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results


Latest News

The company announces the first patient dosed in a Phase 1/1b clinical trial evaluating its novel IL-2 cytokine, DF6215, the seventh Dragonfly-developed drug to enter into clinical trials.

Our Collaborations

DRAGONFLY is a distinctively effective pharma partner.

Dragonfly rapidly develops drugs with our pharma partners in expanding fields from autoimmune disease and oncology, to neuro-inflammation, neuromuscular disease, virology, and beyond.


Our Platform


Two Proprietary Platforms

DRAGONFLY is a clinical-stage biotech that has developed a deep portfolio of drugs built on two unique platforms: first-in-class tri-specific immune engagers (“TriNKET®s”)
and best-in-class CYTOKINEs – each with lead
drugs in the clinic with encouraging results. 

Growing the
Pipeline for Patients

In addition to a set of advanced programs in the clinic or handed off to our pharma partners, DRAGONFLY is developing 30+ TriNKETs® and multiple CYTOKINES across a broad range of fields, including autoimmune and inflammatory diseases, fibrosis, neurology, infectious disease, and oncology.


DRAGONFLY's pipeline is rapidly growing in a number of
therapeutic areas of critical patient need.

bottom of page